B cell receptor CD22
| B-cell receptor CD22 | ||
|---|---|---|
| other names |
B-lymphocyte cell adhesion molecule, BL-CAM |
|
| Properties of human protein | ||
| Mass / length primary structure | 847 amino acids , 95,348 Da | |
| Identifier | ||
| External IDs | ||
B-cell receptor CD22 is a surface protein .
properties
CD22 is a lectin and cell adhesion molecule from the SIGLEC family and binds the B-cell receptor and sialylated (preferably alpha-2,6-bound) glycoproteins such as CD45 . It is made by B cells and is a regulating co-receptor of the B cell receptor. Among other things, it is involved in cell adhesion . Depending on the signal transduction that follows , CD22 can activate the B-cell (via Src ) and thus strengthen the humoral immune response or it is involved in B-cell tolerance (via phosphatases ) . This is done by binding these proteins to the intracellular ITIM motif of CD22. It is glycosylated and phosphorylated . Epratuzumab binds to CD22 and is being studied for the treatment of lupus erythematosus .
Web links
Individual evidence
- ↑ J. Müller, L. Nitschke: The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. In: Nature reviews. Rheumatology. Volume 10, number 7, July 2014, pp. 422-428, doi : 10.1038 / nrrheum.2014.54 , PMID 24763061 .
- ↑ T. Tsubata: Role of inhibitory BCR co-receptors in immunity. In: Infectious disorders drug targets. Volume 12, Number 3, June 2012, pp. 181-190, PMID 22394175 .
- ↑ T. Dörner, A. Shock, DM Goldenberg, PE Lipsky: The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. In: Autoimmunity Reviews . Volume 14, number 12, December 2015, pp. 1079-1086, doi : 10.1016 / j.autrev.2015.07.013 , PMID 26212727 .